Rezolute (RZLT) Change in Interest Receivables (2012 - 2014)
Rezolute (RZLT) posted Change in Interest Receivables of -$1.0 for Q2 2014, down 100.03% sequentially from $3379.0 in Q1 2014, and down 100.03% YoY from $3341.0 in Q2 2013.
Powered by 
Analysis
Rezolute (RZLT) Change in Interest Receivables (2012 - 2014) Analysis & Trends
Rezolute has reported Change in Interest Receivables for 3 years, with the latest figure at -$1.0 in Q2 2014.
- Quarterly Change in Interest Receivables fell 100.03% year-over-year to -$1.0 in Q2 2014, while the trailing twelve-month figure through Mar 2015 was -$1.0 (down 100.01% YoY) and the FY2014 annual result came in at $10211.0, up 136.2% from the prior year.
- Change in Interest Receivables slipped to -$1.0 in Q2 2014 per RZLT's latest filing, from $3379.0 in the prior quarter.
- Over five years, Change in Interest Receivables peaked at $24436.0 in Q2 2012 and troughed at -$30824.0 in Q1 2013.
- A 3-year average of $2967.0 and a median of $3379.0 in 2013 frame the typical range for Change in Interest Receivables.
- The sharpest annual moves came in 2013 and 2014: Change in Interest Receivables plunged 286.0% in 2013, then soared 110.96% in 2014.
- Over 3 years, Change in Interest Receivables stood at $24436.0 in 2012, then sank by 86.17% to $3379.0 in 2013, then plunged by 100.03% to -$1.0 in 2014.
- According to Business Quant data, Change in Interest Receivables over the past three periods registered -$1.0, $3379.0, and $3379.0 for Q2 2014, Q1 2014, and Q4 2013 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2014 | -1.00 |
| Mar 31, 2014 | 3,379.00 |
| Dec 31, 2013 | 3,379.00 |
| Sep 30, 2013 | 3,454.00 |
| Jun 30, 2013 | 3,341.00 |
| Mar 31, 2013 | -30,824.00 |
| Jun 30, 2012 | 24,436.00 |
| Mar 31, 2012 | 16,572.00 |